NDA 022332 · Eli Lilly CO
Adcirca
Tadalafil · Oral · Phosphodiesterase 5 Inhibitor
OrphanLast checked: Nov 20, 2026Latest source record: Sep 15, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
May 22, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
259
70 Phase 3, 23 recruiting
FAERS reports
76,234
51,425 serious, 9,971 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 15, 2025.
ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 ) 1.1 Pulmonary Arterial Hypertension ADCIRCA ® is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).
Mechanism: Tadalafil is an inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Pulmonary arterial hypertension is associated with impaired release of nitric oxide by the vascular endothelium and consequent reduction of cGMP concentrations in the pulmonary vascular smooth muscle. PDE5 is the predominant phosphodiesterase in the pulmonary vasculature. Inhibition of PDE5 by tadalafil increases the concentrations of cGMP resulting in relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- ADCIRCA · TADALAFIL 20MG · TABLET, ORAL · Prescription · TE AB2
Clinical trials
Interventional ClinicalTrials.gov studies with "Tadalafil" as an intervention, any sponsor and status, largest first.
- Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across NationsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00547287 · 2,760 participants · Start Nov 2002
Drug: tadalafil; sildenafil · For: Impotence
Sites: São Paulo, Brazil
- To Determine Effect and Safety of Tadalafil Taken by Men of Different Races and With Different Diseases When Needed for ErectionsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00547417 · 1,933 participants · Start Jul 2003
Drug: tadalafil · For: Impotence
Sites: Dallas, Texas
- Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic HyperplasiaPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00384930 · 1,058 participants · Start Aug 2006 · Primary completion Oct 2007
Drug: tadalafil; tadalafil and 3 more · For: Benign Prostatic Hyperplasia
Sites: Greenwood, Indiana
- A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01937871 · 909 participants · Start Sep 2013 · Primary completion Dec 2015
Drug: 5 mg Tadalafil; Placebo and 1 more · For: Benign Prostate Hyperplasia; Erectile Dysfunction
Sites: Beijing, China; Changchun, China; Changsha, China · 14 sites in all
- A Study in Patients With Erectile DysfunctionPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01122264 · 770 participants · Start May 2010 · Primary completion Jun 2011
Drug: Tadalafil; Sildenafil Citrate · For: Erectile Dysfunction
Sites: Carpentras, France; Chambéry, France; La Bouëxière, France · 45 sites in all
- Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED)Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT00663130 · 759 participants · Start Apr 2004 · Primary completion Jul 2004
Drug: Levitra (Vardenafil, BAY38-9456); Tadalafil · For: Erectile Dysfunction
- A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary SymptomsPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01139762 · 696 participants · Start Sep 2010 · Primary completion Feb 2012
Drug: Tadalafil; Placebo and 1 more · For: Benign Prostatic Hyperplasia; Enlarged Prostate
Sites: Davis, California; Fresno, California; Laguna Hills, California · 65 sites in all
- Efficacy and Safety of DKF-313 in Patients With Benign Prostatic HyperplasiaPivotal-lookingCompleted
Dongkook Pharmaceutical Co., Ltd.Industry
NCT04947631 · 667 participants · Start Jul 27, 2021 · Primary completion Jun 12, 2023
Drug: DKF-313; Dutasteride and 4 more · For: Benign Prostatic Hyperplasia
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea11,617
- headache9,611
- diarrhoea7,571
- nausea6,235
- death5,473
- fatigue5,330
- dizziness4,740
- cough4,315
- pneumonia4,078
- malaise3,537
- vomiting3,308
- fluid retention3,143
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 24 |
| 2005 | 13 |
| 2006 | 15 |
| 2007 | 37 |
| 2008 | 26 |
| 2009 | 49 |
| 2010 | 206 |
| 2011 | 787 |
| 2012 | 1,251 |
| 2013 | 1,755 |
| 2014 | 6,366 |
| 2015 | 6,085 |
| 2016 | 5,849 |
| 2017 | 5,783 |
| 2018 | 6,736 |
| 2019 | 5,852 |
| 2020 | 4,946 |
| 2021 | 4,657 |
| 2022 | 4,940 |
| 2023 | 5,545 |
| 2024 | 5,552 |
| 2025 | 5,853 |
| 2026 | 3,907 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Nov 5, 2026
Adcirca, Tablet, 20 mg (NDC 66302-467-60). Discontinuation of the manufacture of the drug
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Adcirca (Tadalafil)
2024 spending
$23.8M
Beneficiaries
680
5,153 claims
Per beneficiary
$35,037
$67.26 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $55,942,543 |
| 2021 | $43,282,513 |
| 2022 | $33,526,807 |
| 2023 | $29,259,353 |
| 2024 | $23,825,305 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tadalafil.
Curran M, Keating G · Drugs 2003 · Clinical Trial, Controlled Clinical Trial
- Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
Grünig E, Jansa P, Fan F, et al. · J Am Coll Cardiol 2024 · Randomized Controlled Trial, Multicenter Study
- Tadalafil therapy for pulmonary arterial hypertension.
Galiè N, Brundage BH, Ghofrani HA, et al. · Circulation 2009 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Chin KM, Sitbon O, Doelberg M, et al. · J Am Coll Cardiol 2021 · Clinical Trial, Phase III, Comparative Study
- Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, et al. · N Engl J Med 2015 · Multicenter Study, Randomized Controlled Trial
- Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
Erdogan M, Esatoglu SN, Kilickiran Avci B, et al. · Intern Emerg Med 2024 · Systematic Review, Meta-Analysis
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.